Apogee Therapeutics, Inc. (NASDAQ: APGE) related to its sale to AbbVie Inc. Under the terms of the proposed transaction, Apogee shareholders are expected to receive $135.11 per share in cash.
Apogee Therapeutics, Inc. (NASDAQ: APGE) related to its sale to AbbVie Inc. Under the terms of the proposed transaction, Apogee shareholders are expected to receive $135.11 per share in cash.